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Abstract  
 
Background: Methods to identify where new trials may change the interpretation of 
an existing systematic review will facilitate efficient review updating. 
 
Objectives: To consider the use of statistical methods that aim to prioritise the 
updating of a collection of systematic reviews based on preliminary literature 
searches.  
 
Methods: A new simulation based method estimating statistical power and the ratio 
of the weights assigned to the predicted new and old evidence and the existing 
Barrowman n approach are considered. Using only information on the numbers of 
subjects randomised in the “new” trials, these were applied retrospectively, by 
removing recent studies, to existing systematic reviews from the Cochrane Infectious 
Diseases Group.  
 
Results: Twelve systematic reviews were included. When the removed studies were 
reinstated, inferences changed in five of them. These reviews were ranked, in order of 
update priority, 1, 2, 3 , 4 and 11 and 1, 2, 3, 4 and 12 by the Barrowman n and 
simulation based power approaches respectively. The low ranking of one significant 
meta-analysis by both methods was due to unexpectedly favourable results in the 
reinstated study.  
 
Conclusions: This study demonstrates the feasibility of the use of analytical methods 
to inform update prioritisation strategies. Under conditions of homogeneity, 
Barrowman‟s n and simulated power were in close agreement. We encourage further, 
prospective, evaluation of these methods.  
 
Keywords: meta-analysis, systematic review, updating, power, methodology, 
simulation 
 
Running title: Priorities for updating systematic reviews 
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1. Introduction 
Systematic review is an accepted method for synthesising information in many 
research fields, including medicine. As a component of such reviews, meta-analysis is 
used extensively to synthesise quantitative information from multiple studies. Meta-
analysis of (well conducted) randomised controlled trials (RCT) evaluating the 
effectiveness of interventions are considered to provide the highest level of evidence 
for informing treatment decisions. As such, systematic review and meta-analysis 
underpin much of evidence based medicine.(1) 
 
The use of meta-analysis has greatly increased in medicine over the past two decades. 
In 2006 alone there were 2042 articles tagged with the publication type “meta-
analysis” in Medline. Just considering meta-analyses of RCTs, by October 2007, the 
Cochrane database alone included 3,298 completed systematic reviews. The Cochrane 
Collaboration policy is that all reviews should be updated every 2 years; that‟s 4.5 
reviews a day! Now systematic reviews and meta-analyses exist for many 
interventions, the challenge in the future will be updating these and keeping the 
evidence base relevant.  
 
However, systematic reviews can become rapidly out of date as new research 
evidence emerges. In a recent study, 23% of a sample of 100 systematic reviews 
became out-of-date within two years of their publication, and 15% within one year. 
(2) The Cochrane Collaboration updates their reviews as new trials become available, 
but the task is considerable. Indeed, the problem exists for all reviews, and it is just as 
valuable to know when reviews published in journals are out-of-date and new updated 
systematic reviews should be made available. (3)  
 
Updating systematic reviews is often a continual and a very time consuming process 
(it has been suggested an update is as costly and time consuming as conducting the 
original review (4)) and resources are usually limited; much like revising any 
academic paper, the whole document needs reappraising and updating. This includes 
lots of detailed information on results of searching, data extraction of primary and 
secondary outcomes, quality assessment, construction of forest plots, re-interpretation 
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of data, updates to the discussion, and amendments to reference lists etc. The 
identification of new studies is a small fraction of the whole systematic review 
process and resulting document. 
 
This has lead to editors of Cochrane review groups having to make difficult choices 
between removing reviews from the database if they are deemed too out-of-date, 
channel limited resources into updating them or, as done in a recent pilot study, (5) 
„close a review‟ following a judgement that there is not likely to be new evidence in 
the future, or the research question is no longer of interest. As part of the groundwork 
that goes into making this assessment, review groups may (as the Cochrane Infectious 
Disease one currently does) keep literature searches up-to-date and identify all new 
potentially relevant RCTs for inclusion in each review they currently maintain. At this 
point, basic details of the new trials, including the number of participants randomised, 
can be extracted relatively quickly from abstracts supplied by electronic databases.  
This paper considers how, with only minimal information on the new studies, update 
prioritisation strategies can be devised for a collection of existing systematic reviews; 
such as those of review groups within the Cochrane Collaboration. It is hoped use of 
such strategies can help keep clinical recommendations as up-to-date and accurate as 
possible, for a limited resource, and, offer improvements over less strategic update 
strategies such as updating of all reviews according to a perpetual (unordered) rota. 
Indeed, others have observed that the arbitrary Cochrane strategy may result in an 
inefficient use of resources in slowly developing fields or delayed incorporation of 
new knowledge in rapidly evolving fields. (4) 
 
In order to use the methods described in this paper, it is envisaged that persons who 
manage collections of systematic reviews (e.g. Cochrane Editors) would keep details 
of their primary outcome meta-analyses and sample sizes of relevant new studies in 
one spreadsheet. With the sending of a single analysis command, an update 
prioritisation list is generated for all reviews in question. Crucially, the assessment 
can be repeated at any time as and when new studies are published and there are 
resources free to work on review updates. We have developed and make available on 
request (e-mail 1st author) Stata (6) macros to implement all analyses presented in the 
paper. 
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The remainder of this paper is structured as follows. Section 2 outlines an existing and 
a newly adapted method for assessing whether the conclusions of a meta-analysis are 
likely to change when the new evidence is included. Section 3 describes the 
retrospective application of these methods to the reviews containing fixed effect meta-
analyses in the Cochrane Infectious Disease Systematic Review Database. Section 4 
further considers the application of the methods to meta-analyses where heterogeneity 
is present. Section 5, the discussion, concludes the paper. 
 
2. The effect of new evidence on meta-analysis results 
Methods considered to prioritise reviews for updating are outlined below.  
 
2.1 Barrowman’s n 
This method was initially presented by Barrowman et al (7) as a way of identifying 
null (i.e. non statistically significant) meta-analyses that are ripe for updating. 
Barrowman‟s n can be interpreted as the number of additional subjects required (on 
average) to obtain a statistically significant result from a null meta-analysis. They 
derive the following equation for n: 
 
1
22
ZZNn
C
,    [1] 
 
where 
C
Z  is the critical value for the Z statistic used to determine a significant result 
(i.e. in this paper 
C
Z =1.96, corresponding to a two-sided Type I error rate of 5%). Z 
is the z-statistic from the current meta-analysis derived by dividing the estimated 
pooled treatment effect by its standard error and N is the total number of participants 
included in the studies in the meta-analysis.  
 
Using equation 1, the “new participant:n ratio”, i.e. the ratio of the actual number of 
participants in new studies to n (i.e. the predicted number required to obtain statistical 
significance) can be calculated. The higher this ratio, the more chance the updated 
meta-analysis would have a statistically significant result. 
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The original exposition of this method (7) stressed it was only intended to be a quick 
approximate estimate of the amount of new evidence required (although it may be 
sufficiently accurate for purposes of update prioritisation). For example, it does not 
take into account factors such as sampling error in the existing estimate of the 
treatment effect, varying baseline risk between studies, the number of new studies, 
and between study heterogeneity.  
 
2.2 The power of an updated meta-analysis using simulation 
While closed-form expressions for calculating power exist for some simple statistical 
tests, this is not the case for other more complex procedures such as the updating of 
an existing meta-analysis. Fortunately, power of virtually any statistical test can be 
calculated through simulation methods in which data are repeatedly simulated 
stochastically under the alternative hypothesis and analysed. (8) We adapt such 
methods here to calculate the probability of producing a statistically significant result 
when adding further studies (in which the results are consistent with those that already 
exist) to an existing meta-analysis. 
 
Such a method was initially described in the literature (9) in the context of designing 
new studies with enough power to change inferences of the updated meta-analysis in 
which they would ultimately be included. However, the method can be adapted to use 
in an update prioritisation context. When designing new studies, power is typically 
fixed (often at around 80%) and the necessary sample size is derived. In the present 
context, the sample size of the new study(s) is known and it is estimation of power 
which is required for such a sample size. 
 
A non-technical summary of this simulation approach to calculating power when 
adding new studies to an existing meta-analysis is given below, and, full technical 
details can be found elsewhere.(9)  For simplicity, this summary assumes only one 
new study is to be added to the existing meta-analysis, but the approach readily 
generalises to simulating data for multiple new studies. 
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1. From a meta-analysis of the existing studies, a distribution for the effect in a new 
study is derived. An effect size from this distribution is then sampled representing the 
predicted effect in the new study.  
2. Data representing the new study are generated stochastically according to the effect 
sampled in step 1 for a specified sample size. 
3. This simulated study data are then added to the existing meta-analysis, which is 
then re-meta-analysed.  
4. The hypothesis test on which decisions are to be based is then considered and 
whether the null is retained or rejected in favour of the alternative hypothesis 
established at a specified level of statistical significance (often 5%) is noted.  
5. Steps 2 to 4 are repeated a large number of times (K) noting the outcome of the 
hypothesis test each time. 
6. Power is estimated by calculating the proportion of the K simulations in which the 
null hypothesis is rejected at the specified statistical level.   
 
The number of replications (K) used is arbitrary, with the accuracy of the estimation 
of power increasing with K. This general approach can be used with any outcome 
measure and with any meta-analysis model.  
 
For illustration, a worked example for simulating a new study using a fixed effect 
meta-analysis model on the relative risk (RR) scale is given. Details of the 
calculations for other scenarios are available elsewhere. (9) Consider the meta-
analysis in Figure 1a concerning the outcome failure by day 28 treating 
uncomplicated malaria with chloroquine or amodiaquine combined with sulfadoxine-
pyrimethamine. This meta-analysis is considered in more detail below but at present it 
is used to illustrate how the simulation approach works. This meta-analysis has a 
pooled log RR of -1.01 with a variance of 0.322. Assuming the log RR to be 
Normally distributed, an effect size is sampled and exponentiated to produce an 
estimate of the RR in the new study (Stage 1). For simplicity, the event rate in the 
control group of the new study is assumed to be fixed at the un-weighted average of 
the event rates in the three existing studies; which is 0.12 in this instance (although an 
alternative approach to estimating this quantity, and the procedure could be made 
more elaborate to take into account the uncertainty in this quantity). Since RR = 
Probability of an event in the treatment group / Probability of an event in the control 
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group, an estimate of the event rate in the treatment group can be derived using this 
equation and the estimates of the other two quantities. Data for the new study can now 
be simulated (Stage 2) by simulating the number of events from binomial distributions 
for both treatment and control groups for a sample sizes equal to that for the new 
study and probabilities derived above. Stages 3 to 6 can then be conducted.  
 
The specific equations used are dependent on the outcome measure and the meta-
analysis model utilised (10) but the general approach is applicable to any meta-
analysis scenario. (9) In particular, the calculations are more complex in a random 
effects context since the prediction equations need to take into account between study 
heterogeneity. The approach used to prediction is described elsewhere (9) and 
implemented here using an approximate formulae suggested previously (11).  
 
Once power is calculated for each meta-analysis that could potentially be updated, 
they can be ranked in order of priority by their estimated powers (descending order). 
An advantage this approach has over the Barrowman n is that these powers give a 
direct estimate of the likelihood that inferences would change in any particular meta-
analysis. For example, the decision may be taken to only update reviews in which the 
primary meta-analysis had power of 60% or greater etc. 
 
2.3 Other measures used as criteria for updating meta-analyses 
Using the simulation framework described, it is possible to consider power for 
virtually any hypothesis test, or predict any statistic related of the updated meta-
analysis, and these could be used as alternative bases (or in addition) to the power of 
the standard hypothesis test presented above for update prioritisation. For example it 
would be possible to assess the likelihood the effect size of the updated meta-analysis 
lay inside, outside, or, across pre-specified limits representing clinical equivalence (9) 
and could be used to help distinguish identifying statistically significant from 
clinically significant treatment effects. Alternatively, the ratio of the standard error of 
the predicted new estimate of effect to the existing, or, the ratio of the sum of the 
weights (10) allotted to the predicted new and existing studies in the updated meta-
analysis could be used as criterion. These would allow prioritisation based on the 
relative magnitude of new to old evidence (opposed to the results of the studies). All 
these potential indicators or „signals‟, and several more, including the qualitative 
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„signals‟ used elsewhere for determining when systematic reviews are out of date (2),  
are incorporated into Stata (6) macros which were used to conduct all analyses 
presented in this paper (including generating the priority rankings), and are available 
from the first author on request. The next section provides an application of the use of 
the methods to a systematic review database.   
 
3. Retrospective application of the methods  
Here we consider the feasibility and performance of the described methods to assess 
the likelihood a meta-analysis‟ conclusions will change given only the number of 
patients included in new studies not included in the existing meta-analysis. A 
retrospective design was chosen since a prospective study would take an excessive 
amount of time to complete for little or no perceivable benefit. Of course, in practice 
such methods would be used prospectively as tools to assist the decisions regarding 
the timing and prioritisation of updating collections of systematic reviews and meta-
analyses, such as those maintained by the Cochrane Collaboration.  
 
Methods: All 67 completed (as of April 2006) systematic reviews by the Cochrane 
Infectious Diseases Review Group in the Cochrane Collaboration Systematic Review 
Database were considered for potential inclusion. A systematic review was included if 
it met the following criteria: 
 
 Contained a meta-analysis and stated a primary outcome  
 The primary outcome was binary  
 The meta-analysis of the primary outcome contained no cluster randomised trials 
 The meta-analysis of the primary outcome had to contain studies which were 
published over a duration of four or more years (i.e. the date of publication of the 
most recent study included has to be at least three years greater than the first 
study) 
 
For the systematic reviews which did meet criteria 1-4, all trials which were published 
within 3 years of the most recent study included in the primary endpoint meta-
analysis were removed (e.g. if the most recent study was published in 2003 then all 
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studies published in 2001, 2002 & 2003 were removed). A further criterion was then 
applied: 
 
 A meta-analysis of the primary endpoint on the remaining studies had to be 
non-significant at the 5% significance level. 
 
The above process retrospectively identifies meta-analyses which would have been 
non-significant 3 years prior to the inclusion of the most recent study and assumed 
treatment effects were homogeneous between studies.  
 
The two methods described in Section 2 were then applied to these reduced meta-
analysis datasets, to predict the likelihood the updated meta-analysis, including the 
removed studies, would produce a significant treatment effect (at the 5% level). In 
addition, the simulation based approach considered the weights of the predicted 
(updated) to old studies in the updated meta-analysis. 
 
The only information the methods require is the total number of persons randomised 
to the treatment and control groups of the removed studies. Barrowman‟s n and 
corresponding new participant:n ratio were calculated and systematic reviews were 
ranked using the latter.  
 
For the simulation method, for simplicity, it is assumed the control group event rate in 
all the new studies will be equal to the average in the existing studies (estimated by a 
simple unweighted average) for that meta-analysis. Analysis was conducted using the 
outcome measure (i.e. OR or RR) and meta-analysis model (i.e. Mantel-Haenszel, 
Peto or random effects (10)) used in the original Cochrane review. The power and 
ratio of weight given to the predicted new and existing studies in the updated meta-
analysis was then estimated using 5000 simulation replications and systematic 
reviews ranked accordingly. 
 
The results of using Barrowman‟s n and the prioritisation rankings based on power 
and % weight of the new studies were compared and contrasted with each other and 
with the actual results of the updated meta-analyses. 
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Results: Of the 67 reviews in the Cochrane Collaboration Infectious Disease Review 
Group Database, 12 met our inclusion criteria. The meta-analyses used a fixed effect 
model in 10 of these reviews and a random effects model was used in the remaining 
two.  In total, 55 reviews were excluded: 5 reviews did not contain any trials or did 
not conduct meta-analysis; the primary outcome of 4 reviews was not binary; 2 
reviews analysed cluster randomised trials; and the results were still significant after 
the recent studies had been omitted in 14 reviews. In the remaining 30 cases, the small 
number of trials in the meta-analyses prevented the required retrospective analysis. 
While full details of the included systematic reviews are available elsewhere, (12-23) 
a brief description of the topic of each review is provided in the second column of 
Table 1. 
 
Applying Barrowman‟s n: In Table 1 the Barrowman n and new participant:n ratio for 
the meta-analysis of the primary endpoint within each review is provided. The 
reviews are ranked on the magnitude of the ratio in descending order. Five of the 12 
systematic reviews have ratios greater than one indicating more new evidence has 
accumulated than the Barrowman‟s n method estimated to be required to obtain 
statistical significance. The actual p-value for the updated meta-analysis is provided in 
the last column of Table 1. It can be seen that five of the 12 meta-analyses were 
actually statistically significant at the 5% level when updated. These five meta-
analyses were ranked 1, 2, 3, 4 and 11 in order of update priority. Hence, if the five 
meta-analyses with a new participant ratio greater than one had been identified for 
update, four out of the five meta-analyses would have changed inferences at the 5% 
level. However, the change in inferences in review ranked 11 (drugs for treating 
tapeworm infection of the brain (20)) would have been missed. Other than for review 
11, there is good agreement between the rank priority given to each review and the p-
value of the updated meta-analysis. 
 
Applying power by simulation: The estimated power of each of the updated meta-
analyses calculated by simulation is displayed, ranked in descending order, in column 
3 of Table 2.  The first thing to note is that only one of the updated meta-analyses 
achieved power over 80%  - a level often considered acceptable when carrying out 
primary research - and six out of the 12 do not achieve 50% power.  The five meta-
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analyses in which inferences did change were ranked 1, 2, 3, 4 and 12. There was 
close agreement between the ranks given to this and the Barrowman n method. 
 
Ratio of the weights given to the new and old evidence: The estimate of the ratio of 
the weights are given to the new and old evidence in the simulated updated meta-
analysis and associated rankings are provided in the final two columns of Table 2. 
While the systematic review ranked highest (Rotavirus vaccine for preventing 
diarrhoea (23)) is consistent with previous criteria, much less agreement is seen 
beyond this.  
 
Detailed examination of two meta-analyses: For illustration, two of the meta-analyses 
are presented in more detail. Firstly, the review ranked second for updating by 
Barowman:n ratio and power and ranked fourth based on the weight ratio - 
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating 
uncomplicated malaria (21). The primary outcome in the meta-analysis is failure by 
day 28. Figure 1a presents the meta-analysis used to base the calculation on with the 
two most recent studies removed (references to individual trials in each meta-analysis 
are available from the original Cochrane reviews). This meta-analysis suggests the 
treatment is potentially efficacious (RR = 0.37 (95% CI 0.12 to 1.11)) but not 
statistically significant at the 5% level (p = 0.07). When the two removed studies are 
re-instated into the meta-analysis (Figure 1b), although the pooled RR increases 
considerably to 0.64, it is now highly statistically significant (p = 0.01). Examination 
of the weightings (10) given to each study in the meta-analysis in Figure 1b indicates 
that the two newest studies, initially removed, are together given over 80% of the 
weight in the meta-analysis (resulting in an actual weight ratio of 4.5), reflecting the 
considerable “new” evidence that was available and hence the potential benefit in 
updating the review. Note this observed weight ratio is higher than that predicted by 
the simulation model (1.6) due to the much higher event rates observed in the two 
„new‟ studies compared to the existing studies from which predictions on the new 
studies were made. 
 
Secondly, we consider the review of drugs for treating tapeworm infection of the 
brain (20) which was ranked 11 and 12 by the Barrowman n and simulation 
approaches respectively but (unpredictably) produced a statistically significant result 
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when updated. The meta-analysis on which calculations were based, with one study 
removed is displayed in figure 2a. Here three studies exists, two of which are much 
more precise than the third. These two studies both have point estimates close to the 
null (RR of 1.04 and 0.86). The pooled point estimate is also close to the null (RR = 
0.92) with relatively high precision (95% CI 0.78 to 1.09). The excluded study has a 
“surprising” result with a large statistically significant beneficial effect (RR 0.49 
(95% CI 0.25 to 0.96)). This has an “unpredictable” effect on the meta-analysis of 
making the treatment effect statistically significant overall. Hence, all methods 
“failed” to give high priority to this review for updating because the new evidence 
was inconsistent from what was predicted given the previous three studies (although 
the weight ratio prediction was reasonably accurate). It is interesting to note that, 
following inclusion of the later study with the large beneficial effect, it is probably not 
reasonable to consider the study effects as homogeneous, which invalidates the fixed 
effect assumption made using the simulation method. 
 
Relationship between methods: As a way of assessing the relationship between the 
Barrowman n and power by simulation methods, the power of updating each meta-
analysis was calculated by the simulation method for a study with size equal to that 
calculated as the Barrowman n. The results are presented in the final column of Table 
2. The estimated power ranges from 32% to 58% with an average of 47% (power 
could not be determined for the mycobacterium vaccine for TB review (19) due to the 
extreme nature of the associated Barrowman n). Since Barrowman‟s n is a calculation 
of the size a study would have to be to obtain a significant result in a meta-analysis on 
average, or put another way, 50% of the time, these estimated powers all around 50% 
are not surprising and suggest close agreement between methods. An interesting 
observation is that the estimated power from the two meta-analyses which use a 
random effects model are furthest away from 50% suggesting potentially poorer 
agreement between methods when the simulation approach models between study 
heterogeneity.  
 
The next section considers in further detail the application of the methods in a 
heterogeneous treatment effects scenario.  
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4. Use of methods with heterogeneous treatment effects 
 
In this section we consider a further meta-analysis which has heterogeneous treatment 
effects. For illustration, the event data for the most recent study are (retrospectively) 
removed and we then apply the Barrowman n method and the simulation approach to 
predict the power and weight ratio of new to old studies using both fixed and random 
effect meta-analysis models. 
 
The meta-analysis comes from the Cochrane review of chemotherapy alone versus 
endocrine therapy alone for metastatic breast cancer (24) and the outcome is the 
tumour response rate of endocrine therapy versus chemotherapy. In the original 
review a fixed effect analysis (despite large heterogeneity being estimated) on the 
relative risk scale was carried out.  We use the odds ratio scale here (although this 
makes little difference to the calculations) and consider both fixed and random effect 
analyses and compare the results. 
 
Figures 3a and b present the fixed and random effect meta-analysis models for the 
earliest 6 studies included in the meta-analysis respectively. It can be seen that choice 
of meta-analysis model changes the pooled effect considerably with the fixed effects 
model estimating the treatment effect as 1.36 (95% CI 0.99 to 1.86) and the random 
effect as 1.17 (0.53 to 2.60). The I
2
 statistic (25) (which estimates the proportion of 
total variation in point estimates attributable to heterogeneity rather than sampling 
error) for this dataset is 73% (i.e. reasonably large), and the test for heterogeneity has 
a p-value of <0.001. The excluded study from these plots is published in 1992 (Dixon 
et al.) that randomised approximately thirty patients each to the two treatment groups.  
 
For the fixed effect analysis, the Barrowman n is 26, hence the new participant ratio is 
2.29 for a study of the size actually conducted. The power of the new study to change 
inferences of the meta-analysis by simulation under a fixed effect model is estimated 
to be 52.7%. Hence, using both methods one would conclude there would be at least a 
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reasonable chance inferences changed if the meta-analysis were updated despite the 
weight ratio being a low 0.08. 
 
For the random effects analysis, the Barrowman n was 2846 - several orders of 
magnitude larger than for the fixed effects - and with a low new participant ratio of 
0.01. The power by simulation is estimated to be 0% (i.e. none of the simulations 
produced a significant result) with a weight ratio of 0.15 (this is larger than under the 
fixed effect scenario since studies get more equal weighting under random effects 
models). Hence, using any of the indicators, one would conclude there would be very 
little chance that inferences would change if the meta-analysis were updated. This 
implies the meta-analysis model choice can be critical to updating decisions. 
 
Figures 3c and d indicate the actual meta-analysis results when the most recent study 
was reinstated. Under the fixed effects model the treatment effect did become 
significant (OR = 1.38 (1.02 to 1.88) but not under a random effects model (1.26 
(0.62 to 2.56)) which coincides well with the predictions both methods make.  
 
Given the potential difference in results between fixed and random effect model 
predictions, it is important to consider how the decision of which method to use is 
made, in a particular context. This is made more difficult by knowledge that the test 
for heterogeneity has low power when the number of studies is small; (26) which they 
typically will be for many medical interventions. 
 
5. Discussion 
A recent systematic review (4) suggests that the whole process of updating systematic 
reviews is under-researched and that the importance of updating has not been well 
recognised. We have begun to rectify this situation by exploring the use of methods 
based on both approximate closed form solutions and simulation methods to help 
indicate when systematic reviews need updating, and to create a prioritisation order 
for updating across a collection of such reviews. Such prioritisation will become 
increasingly important over time as the number of published reviews, and, hence 
burden of updating, increases. While the focus of this paper has been on meta-
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analyses of interventions the methods readily translate to other areas of application 
(e.g. environmental health etc). 
 
We believe the results presented in this paper are encouraging enough to justify 
pursuing their further evaluation. We hope a prospective pilot can be conduced to 
assess the added value of using the methods over current updating practices. 
 
Barrowman‟s n and simulated power approaches produce results in close agreement 
under conditions of homogeneity, and when the new studies are consistent with those 
meta-analysed previously. However, we believe, the simulation approach will 
generally produce more accurate results over a broader range of scenarios, including 
when between study heterogeneity is present, due to a more realistic modelling of the 
meta-analysis data.  
 
In reality, there would be no need to restrict the update priority assessment to only 
“significant” meta-analyses if the simulation approach is used. (Barrowman‟s n was 
intended for use only in situations where the existing meta-analysis is non-
significant.) For presently “significant” meta-analyses it would be possible to 
calculate power to become “non-significant” – i.e. the criteria are reversed but the 
principle is the same (this possibility is programmed in the developed software). 
 
Restricting attention to methods which only consider changes in statistical 
significance have important limitations, due to their arbitrary nature (27). Of course, 
important changes in effect sizes may happen that are not associated with changes in 
statistical significance. We consider a further measure in the ratio of the predicted 
total weightings given to the predicted new and existing evidence. We like this 
measure since it takes into account the relative magnitude of new evidences as well as 
the impact of (any) between study heterogeneity on the analysis (big studies get 
relatively less weight the more heterogeneity there is present). The further possibility 
of using clinical limits of equivalence has been discussed above and in more detail 
elsewhere. (9) 
 
In fact, the simulation method could be used to calculate prioritisation based on any 
quantitative measure relating to the updated meta-analysis.  Recent work (2) compiled 
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a list of further potential „signals‟ which were used to identify potentially out of date 
systematic reviews. These included both quantitative and qualitative measures. While 
we have implemented all the quantitative methods in the software, further work is 
needed to evaluate the relationships between signals and evaluate the possibility of 
using more complicated composite updating criteria based on multiple measures or 
„signals‟. Using multiple measures, it may also be possible to define criteria to 
establish when enough evidence has been accrued in a given topic and the systematic 
review can be deemed decisive. A further extension would be to place the whole 
process in a fully decision theoretic framework, and use value of information 
methods, to equate cost of updating to the benefit (in monetary terms) of the update. 
(28) A further area of potentially fruitful research would be to assess how good 
predictions of new evidence are using only the information in the existing systematic 
review. If this were possible, it would mean the methods presented here could be 
adapted to be used even when literature searches are not kept up-to-date.  
 
When the new evidence is not consistent with the existing meta-analysis then none of 
the approaches considered will work well. Reasons why new evidence may be 
inconsistent with previous evidence include pipeline reporting biases (29), “drift” in 
the effectiveness of the intervention, or chance. It is hard to envisage a complete 
solution to this problem, but systematic differences in effects between studies could 
be accounted for by including covariates in the meta-analysis models. Further, 
perhaps, when searching for new trials, special status could be given for those with 
results which are extreme compared to the trials in the existing meta-analysis. 
 
Below, we make some observations relating to the details of the simulation methods 
we have used. Unlike previous, related, work (9) predicting future study results using 
meta-analysis, we do not use Bayesian methods in this paper or the developed 
software. We took the decision that the extra computational burden and software 
requirements would make the software less user-friendly. We felt this outweighed the 
benefits of a slightly more accurate prediction model afforded by Bayesian methods 
(for the random effect context) for the priority updating purposes considered in the 
paper. This would not necessarily be the case if one were designing a future study for 
an individual meta-analysis context (as considered in the previous paper) where 
accuracy is arguably more crucial and the computational burden will be much lower.  
 18 
A related technical issue under random effect modelling is that standard meta-analysis 
methods ignore the uncertainty in the estimation of the between study heterogeneity 
parameter, which can be large when there are few studies in the meta-analysis (a 
context in which such methods may often be applied). Classical (30, 31) and Bayesian 
(32) solutions to allow for such uncertainty are available but rarely used in practice. 
However, as explained above, we traded simplifications in modelling for lower 
computational burden. 
 
In predicting future studies we make the assumption that the underlying event rate in 
new studies is the same as the average of the control rates in the observed studies. 
Adding further sophistication to the simulation process would allow this to be relaxed 
in favour of imputing a stochastic estimate derived from the observed distribution of 
baseline rates. In fact, to do this it would be necessary to modify the standard meta-
analysis models since these make no assumptions about the baselines (i.e. each one is 
estimated independently as „nuisance‟ parameters and they are not assumed to be 
related to each other in any way). Incorporating random effects for baseline effects (as 
well as treatment effects) (33) would be one approach allowing stochastic baseline 
predictions to be made. 
 
 
We fully acknowledge that further information relating to a systematic review not 
contained in the meta-analysis of the primary outcome may be pertinent to updating.  
For example, new information on adverse effects, or the development of competing 
interventions may be critical. Also, it may be advantageous to consider the prevalence 
and severity of the disease in question when setting update priorities. Also, 
methodology may have improved since the original systematic review was done and 
hence updates using the new methodology may be desirable. The first analyses 
identifying predictors of the speed a systematic review will go out of date have been 
published. (2) We support the development of a broader approach to update 
prioritisation which could incorporate this information and which the methods 
presented in this paper could feed into, but acknowledge that this is some way off.  
 
An alternative approach to updating reviews would be to update the meta-analysis of 
the primary outcome in all reviews but only progress with the updating of the total 
 19 
systematic review if inferences actually change. However, such an approach would 
induce bias in the published literature since effect sizes would be over-estimated 
because of the updating process being of a “data dredging” nature. Conversely, usinga 
strategic approach to updating may actually reduce the problem of multiple testing 
(34) in updated meta-analysis which means (N.B. even if no treatment effect exists, 
the null hypothesis will be rejected eventually if the meta-analysis is updated enough 
times). Further, methods are emerging to control for this when updating meta-analysis 
and these could be used in conjunction with the methods presented here. (35) 
 
There may be merit in integrating an assessment of how much further evidence is 
required on a topic into the publication of the initial systematic review. Such 
information would be useful to inform the design of new studies as well as providing 
guidance on when an update would be worthwhile. If such an endeavour was seen as a 
requirement of systematic review, it would help bring coherence to the way new 
research was conducted. Of course, if all new studies were designed to adequately 
power an updated meta-analysis (9) then it would always be worthwhile updating the 
meta-analysis and thus reducing the need for a priority setting process such as the 
ones considered here, but as this study shows this is often not the case. 
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Table 1 Results of applying Barrowman n calculations to the 12 primary outcome meta-analyses  
Rank by 
Barrowman 
new 
participant 
ratio  
Review 
Total number 
of studies 
(number 
removed) 
Number of 
subjects in 
existing ( non-
removed) 
studies 
Barrowman 
n 
Actual total 
number of new 
subjects in 
removed studies 
New 
participant 
ratio* 
P-value of 
the updated 
meta-
analysis 
1 Rotavirus vaccine for preventing diarrhoea (23) 7 (5) 410 365 7397 20.28 0.01 
2 Chloroquine or amodiaquine combined with 
sulfadoxine-pyrimethamine for treating uncomplicated 
malaria (21) 
5 (2) 172 38 289 7.6 0.01 
3 Steroids for tuberculous meningitis (12) 6 (3) 344 66 251 3.8 0.02 
4 Artemisinin derivatives for treating severe malaria 
(22) 
11 (3) 1379 
300 700 2.33 
0.02 
5 Reduced osmolarity oral rehydration solution for 
cholera (13) 
5 (3) 223 
194 393 2.03 
0.26 
6 Antibiotics for treating salmonella gut infections (14) 5 (1) 339 67 46 0.69 0.07 
7 Routine anticovulsants for cerebral malaria (15) 3 (1) 233 599 340 0.57 0.36 
8 High first dose quinine regimen for severe malaria 
(17) 
3 (1) 72 
191 72 0.38 
0.43 
9 Interventions for melioidosis (16) 4 (2) 182 1157 314 0.27 0.69 
10 Drugs to prevent malaria-related illness in pregnant 
women and death in the newborn (18) 
4 (2) 1431 
7186 1459 0.2 
0.90 
11 Drugs for tapeworm of the brain (20) 4 (1) 242 743 63 0.08 0.04 
12 Mycobacterium vaccae immunotherapy for treating 
tuberculosis (19) 
5 (3) 476 3718118 1265 0 0.60 
* The ratio of the actual total number of participants in new studies to the predicted number required to obtain statistical significance 
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Table 2 Results of applying power by simulation to the 12 primary outcome meta-analyses 
Rank 
by 
simulated 
power  
Review 
Estimated 
power when 
adding new 
studies 
P-value of 
the updated 
meta-
analysis 
Rank by 
Barrowman 
new 
participant 
ratio 
Estimated power 
when adding 
new study of 
Barrowman n 
size 
Meta-analysis  
model used 
Ratio of 
weight 
given to new 
and old studies 
in meta-
analysis 
Rank by 
weight 
ratio 
estimate 
1 Rotavirus vaccine for preventing diarrhoea (23) 89% 0.01 1 32% Random 15.7 1 
2 Chloroquine or amodiaquine combined with 
sulfadoxine-pyrimethamine for treating uncomplicated 
malaria (21) 
79% 0.01 2 44% Fixed 1.6 4 
3 Steroids for tuberculous meningitis (12) 67% 0.02 3 46% Fixed 0.72 9 
4 Artemisinin derivatives for treating severe malaria (22) 64% 0.02 4 58% Random 0.45 10 
5 Reduced osmolarity oral rehydration solution for 
cholera (13) 
62% 0.26 5 48% Fixed 1.7 3 
6 Antibiotics for treating salmonella gut infections (14) 53% 0.07 6 54% Fixed 0.19 12 
7 Routine anticovulsants for cerebral malaria (15) 34% 0.36 7 46% Fixed 1.3 6 
8 Interventions for melioidosis (16) 27% 0.69 9 52% Fixed 1.5 5 
9 Drugs to prevent malaria-releated illness in pregnant 
women and death in the newborn (18)  
20% 0.90 10 54% Fixed 1.0 7 
10 Mycobacterium vaccae for treating tuberculosis (19)  19% 0.60 12 NA* Fixed 2.4 2 
11 High first dose quinine regimen for severe malaria (17) 17% 0.43 8 46% Fixed 1.0 7 
12 Drugs for tapeworm of the brain (20) 6% 0.04 11 42% Fixed 0.28 11 
* Barrowman n too large for this study to calculate power 
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Figure 1 Primary outcome from Cochrane Systematic review of chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating 
uncomplicated malaria: Failure by day 28 
 
 
 
a) Two most recent studies removed b) Two most recent studies reinstated 
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Figure 2 Primary outcome from Cochrane Systematic review on drugs for treating tapeworm infection of the brain: Cyst persistence 
 
a) Most recent study removed b) Most recent study reinstated 
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Figure 3 Chemotherapy versus endocrine therapy for metastatic breast cancer: Tumour response rate 
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b) Random effect analysis – most recent study removed 
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c) Fixed effect analysis – most recent study reinstated 
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d) Random effect analysis – most recent study reinstated  
NOTE: Weights are from random effects analysis
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c) Fixed effect analysis – most recent study reinstated 
Overall  (I-squared = 75.0%, p = 0.001)
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d) Random effect analysis – most recent study reinstated  
NOTE: Weights are from random effects analysis
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